Table 2.

Changes in laboratory measures on voxelotor

Wk 4Wk 8Wk 12
dHb, g/dL 1.2 (0.4-1.5)  0.9 (0.4-1.2)  0.8 (0.2-1.4)  
dRetic, % −2.8 (−3.3 to −0.7)  −1.2 (−4.2 to 0.1)  −1.4 (−2.5 to −0.4)  
dWBC, 1000/μL −1.0 (−1.2 to −0.2)  0.4 (−2.0 to 1.4) −0.8 (−1.6 to −0.1)  
dLDH, U/L — — 27 (−10 to 64) 
dBilirubin, μmol/L — — −0.9 (−1.3 to −0.5)  
Wk 4Wk 8Wk 12
dHb, g/dL 1.2 (0.4-1.5)  0.9 (0.4-1.2)  0.8 (0.2-1.4)  
dRetic, % −2.8 (−3.3 to −0.7)  −1.2 (−4.2 to 0.1)  −1.4 (−2.5 to −0.4)  
dWBC, 1000/μL −1.0 (−1.2 to −0.2)  0.4 (−2.0 to 1.4) −0.8 (−1.6 to −0.1)  
dLDH, U/L — — 27 (−10 to 64) 
dBilirubin, μmol/L — — −0.9 (−1.3 to −0.5)  

Data are reported as median (IQR). P values were obtained from a 2-sided paired Wilcoxon signed-rank test.

dBilirubin, changes from pretreatment levels in bilirubin at 4, 8, and 12 wk of treatment; dHb, changes from pretreatment levels in Hb at 4, 8, and 12 wk of treatment; dLDH, changes from pretreatment levels in LDH at 4, 8, and 12 wk of treatment; dRetic, changes from pretreatment levels in reticulocytes at 4, 8, and 12 wk of treatment; dWBC, changes from pretreatment levels in white blood cell count at 4, 8, and 12 wk of treatment.

P < .05.

P < .01.

P < .005.

or Create an Account

Close Modal
Close Modal